Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Tax ProvisionsTax Rate
Others
Ratios

Lexaria Bioscience (LEXX) EBIT (2017 - 2025)

Historic EBIT for Lexaria Bioscience (LEXX) over the last 12 years, with Q4 2025 value amounting to -$1.6 million.

  • Lexaria Bioscience's EBIT rose 4151.61% to -$1.6 million in Q4 2025 from the same period last year, while for Nov 2025 it was -$10.8 million, marking a year-over-year decrease of 4735.26%. This contributed to the annual value of -$11.9 million for FY2025, which is 10650.91% down from last year.
  • Latest data reveals that Lexaria Bioscience reported EBIT of -$1.6 million as of Q4 2025, which was up 4151.61% from -$2.7 million recorded in Q3 2025.
  • Lexaria Bioscience's EBIT's 5-year high stood at -$668005.0 during Q1 2024, with a 5-year trough of -$3.8 million in Q2 2025.
  • For the 5-year period, Lexaria Bioscience's EBIT averaged around -$1.9 million, with its median value being -$1.7 million (2024).
  • In the last 5 years, Lexaria Bioscience's EBIT soared by 4953.22% in 2024 and then plummeted by 31182.51% in 2025.
  • Quarter analysis of 5 years shows Lexaria Bioscience's EBIT stood at -$2.0 million in 2021, then grew by 15.38% to -$1.7 million in 2022, then skyrocketed by 32.81% to -$1.1 million in 2023, then plummeted by 136.2% to -$2.7 million in 2024, then surged by 41.52% to -$1.6 million in 2025.
  • Its last three reported values are -$1.6 million in Q4 2025, -$2.7 million for Q3 2025, and -$3.8 million during Q2 2025.